Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Gilead Sciences, Inc.NASDAQ: GILD

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures turns positive

Q2 FY2026 capital expenditures was $117M, compared with -$107M a year earlier. Trailing-twelve-month capital expenditures was -$352M. Over 3 fiscal years it compounded at -8.2% a year.

Context

  • Capital expenditures amounted to 1.9% of revenue in FY2025, unchanged from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near $117M or moves back toward the trailing-twelve-month quarterly average of -$88M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$117M+200.0% QoQ
Last fiscal yearDec 2025
-$563M+7.6% YoY
LTMJun 2026
-$352M-29.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+209.3%——
1 year+7.6%——
3-year CAGR-8.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(563M) USD
Year-over-year change
-7.6%

Capital Expenditures vs competitors

How GILD compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -29.5% is the 7th highest of 9, against a peer median of -19.5%.
  • Capital expenditures amounts to 1.2% of revenue for GILD, versus a peer median of 5.3%.
GILD Competitors
Capital Expenditures for GILD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$8.03B USD-26.9%+38.0%10.1%
JNJJohnson & JohnsonLTM Sep 2026$5.57B USD+8.6%+6.4%5.6%
AZNAstraZeneca PLCLTM Sep 2026$4.01B USD-28.0%+31.9%6.5%
MRKMerck & Co., Inc.LTM Jun 2026$3.9B USD+2.4%-2.1%5.9%
NVSNovartis AGLTM Jun 2026$2.57B USD-35.5%-11.4%4.6%
SNYSanofiLTM Jun 2026€2.52B EUR—-1.8%5.2%
PFEPfizer Inc.LTM Jun 2026$2.42B USD-12.1%-6.7%3.8%
GSKGSK plcLTM Jun 2026£1.76B GBP-42.4%-2.2%5.3%
ABBVAbbVie Inc.LTM Jun 2026$1.3B USD+24.2%+20.4%2.0%
GILDGilead Sciences, Inc.LTM Jun 2026$352M USD-29.5%-8.2%1.2%
Peer median (excluding GILD) —-19.5%-1.8%5.3%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income6.2B4.59B5.67B480M8.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
Deferred Income Tax(116M)(1.55B)(962M)(1.84B)160M
Stock-Based Compensation635M644M766M835M894M
Change in Working Capital489M(1.76B)(2.3B)(880M)(3.95B)
Accounts Receivables313M(406M)157M139M(367M)
Inventory11M(310M)(842M)(426M)(1.04B)
Accounts Payables(118M)226M(347M)290M(132M)
Other Working Capital283M(1.27B)(1.27B)(883M)(2.41B)
Other Non-Cash Items2.13B5.05B2.15B9.47B1.64B
Operating Cash Flow11.38B9.07B8.01B10.83B10.02B
Capital Expenditures(579M)(728M)(585M)(523M)(563M)
Acquisitions (Net)(1.58B)(1.8B)(1.15B)(4.84B)(1.07B)
Purchases of Investments(3.9B)(1.94B)(2.37B)(736M)(4.07B)
Sales of Investments2.91B2B1.84B2.59B909M
Other Investing Activities19M(1M)058M3M
Investing Cash Flow(3.13B)(2.47B)(2.27B)(3.45B)(4.79B)
Debt Repayment(4.75B)(1.5B)(270M)1.49B(1.79B)
Common Stock Issued169M309M232M422M408M
Common Stock Repurchased(546M)(1.4B)(1B)(1.15B)(1.92B)
Dividends Paid(3.61B)(3.71B)(3.81B)(3.92B)(4B)
Other Financing Activities(145M)(173M)(278M)(281M)(440M)
Financing Cash Flow(8.88B)(6.47B)(5.13B)(3.43B)(7.75B)
Effect of Forex Changes(35M)(63M)57M(40M)92M
Net Change in Cash(659M)74M673M3.91B(2.43B)
Free Cash Flow10.81B8.34B7.42B10.31B9.46B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.